Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiao, Chen, Jinbo, Ou, Zhenyu, Chen, Haige, Liu, Zheng, Chen, Minfeng, Zhang, Ruiyun, Yu, Anze, Cao, Rui, Zhang, Enchong, Guo, Xi, Peng, Bo, Deng, Dingshan, Cheng, Chunliang, Liu, Jinhui, Li, Huihuang, Zou, Yihua, Deng, Ruoping, Qin, Gang, Li, Wenze, Wang, Lue, Chen, Tao, Pei, Xiaming, Gong, Guanghui, Tang, Jiansheng, Othmane, Belaydi, Cai, Zhiyong, Zhang, Chunyu, Liu, Zhi, Zu, Xiongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729796/
https://www.ncbi.nlm.nih.gov/pubmed/36265483
http://dx.doi.org/10.1016/j.xcrm.2022.100785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729796/
https://www.ncbi.nlm.nih.gov/pubmed/36265483
http://dx.doi.org/10.1016/j.xcrm.2022.100785

Ejemplares similares